| Announced on | Meeting on |
| Aug 06, 2024 | Aug 12, 2024 |
| Quarterly Results | |
| May 16, 2024 | May 23, 2024 |
| Audited Results | |
| Feb 02, 2024 | Feb 08, 2024 |
| Quarterly Results | |
| Oct 30, 2023 | Nov 04, 2023 |
| Quarterly Results | |
| Aug 04, 2023 | Aug 10, 2023 |
| Quarterly Results | |
Orchid Pharma Share Price
NSE
- Open1,410.85
- High1,417.45
- Low1,376.10
- Prev Close1,403.85
- Volume97,168
- VWAP(₹)1,401.05
Orchid Pharma share price insights
Employee & Interest Expense
Company has spent 2.0% of its operating revenues towards interest expenses and 8.5% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)Stock Returns vs Nifty Midcap 100
Stock gave a 3 year return of 237.87% as compared to Nifty Midcap 100 which gave a return of 112.53%. (as of last trading session)Stock Returns vs Nifty Pharma
Stock generated 237.87% return as compared to Nifty Pharma which gave investors 64.02% return over 3 year time period. (as of last trading session)Orchid Pharma Share Price Update
Orchid Pharma Ltd. share price moved up by 0.03% from its previous close of Rs 1,403.85. Orchid Pharma Ltd. stock last traded price is 1,404.20
Share Price Value Today/Current/Last 1,404.20 Previous Day 1,403.85
Orchid Pharma Share Price Returns
| 1 Day | 0.03% |
| 1 Month | 2.48% |
| 3 Months | 39.58% |
| 1 Year | 162.22% |
| 3 Years | 242.15% |
| 5 Years | N.A. |
Key Metrics
| PE Ratio(x) | 63.85 |
| EPS - TTM(₹) | 21.99 |
| MCap(₹ Cr.) | 7,121.98 |
| MCap Rank | 46 |
| PB Ratio(x) | 6.09 |
| Div Yield(%) | 0.00 |
| Face Value(₹) | 10.00 |
| 52W High(₹) | 1,590.00 |
| 52W Low(₹) | 432.05 |
| MCap/Sales | 6.47 |
| Beta(1 Month) | 0.76 |
| BV/Share(₹) | 230.58 |
Orchid Pharma Share Recommendations
Mean recosCurrent
STRONG BUY
3 Analysts
Strong
SellSellHoldBuyStrong
Buy
SellSellHoldBuyStrong
Buy
Analyst Trends
| Ratings | Current | 1W Ago | 1M Ago | 3M Ago |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 |
| Hold | - | - | - | - |
| Sell | - | - | - | - |
| Strong Sell | - | - | - | - |
| # Analysts | 3 | 3 | 3 | 3 |
ADVERTISEMENT
Orchid Pharma News & Analysis
Disclosure Regarding The Order Passed By Goods And Service Tax Department
AnnouncementsChairman Speech- 31St Annual General Meeting Of Orchid Pharma Limited Held On August ..
AnnouncementsVoting Results For The 31St Annual General Meeting Of Orchid Pharma Limited
AnnouncementsShareholder Meeting / Postal Ballot-Scrutinizer''s Report
Announcements
ADVERTISEMENT
Orchid Pharma Financials
Consolidated
Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Total Income 251.98 230.46 228.21 207.11 184.81 Total Income Growth (%) 9.34 0.99 10.19 12.07 -12.67 Total Expenses 220.36 196.60 194.47 183.28 168.49 Total Expenses Growth (%) 12.08 1.10 6.10 8.78 21.90 EBIT 31.62 33.86 33.74 23.83 16.32 EBIT Growth (%) -6.61 0.36 41.58 46.00 -77.77 Profit after Tax (PAT) 29.35 32.96 29.43 19.80 9.40 PAT Growth (%) -10.94 11.97 48.62 110.57 -84.10 EBIT Margin (%) 12.55 14.69 14.78 11.51 8.83 Net Profit Margin (%) 11.65 14.30 12.90 9.56 5.09 Basic EPS (₹) 5.79 6.81 6.18 4.30 1.85 All figures in Rs Cr, unless mentioned otherwise
InsightsEmployee & Interest Expense
Company has spent 2.0% of its operating revenues towards interest expenses and 8.5% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Total Assets 1,553.87 1,225.21 1,110.56 1,237.25 1,721.66 Total Assets Growth (%) 26.83 10.32 -10.24 -28.14 -44.05 Total Liabilities 384.41 536.56 463.18 584.34 697.30 Total Liabilities Growth (%) -28.36 15.84 -20.73 -16.20 -81.56 Total Equity 1,169.47 688.65 647.38 652.91 1,024.36 Total Equity Growth (%) 69.82 6.37 -0.85 -36.26 - Current Ratio (x) 3.04 1.35 1.87 3.87 3.25 Total Debt to Equity (x) 0.11 0.48 0.41 0.66 0.49 Contingent Liabilities 87.93 48.71 24.87 0.19 0.97 All figures in Rs Cr, unless mentioned otherwise
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Net Cash flow from Operating Activities 125.99 18.34 92.47 23.59 80.80 Net Cash used in Investing Activities -312.03 -31.21 112.94 67.21 167.11 Net Cash flow from Financing Activities 167.04 31.17 -216.80 -164.99 -250.33 Net Cash Flow -19.00 18.29 -11.39 -74.20 -2.42 Closing Cash & Cash Equivalent 3.60 22.60 4.31 15.69 89.89 Closing Cash & Cash Equivalent Growth (%) -84.06 424.71 -72.56 -82.54 -2.62 Total Debt/ CFO (x) 1.07 18.07 2.90 18.25 6.21 All figures in Rs Cr, unless mentioned otherwise
InsightsIncrease in Cash from Investing
Company has used Rs 312.03 cr for investing activities which is an YoY increase of 899.65%. (Source: Consolidated Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Return on Equity (%) 7.88 6.72 -0.30 -17.84 -12.79 Return on Capital Employed (%) 8.37 5.65 -2.86 -4.00 -8.23 Return on Assets (%) 5.93 3.78 -0.17 -9.41 -7.61 Interest Coverage Ratio (x) 8.65 3.20 1.94 -0.86 -30.52 Asset Turnover Ratio (x) 0.59 0.57 0.48 36.37 29.50 Price to Earnings (x) 57.80 33.90 -625.00 -86.96 -0.16 Price to Book (x) 4.53 2.28 1.79 15.41 0.02 EV/EBITDA (x) 36.52 18.14 22.86 161.10 -350.31 EBITDA Margin (%) 17.27 15.47 11.10 14.44 -0.19
ADVERTISEMENT
Peer Comparison
NAME 1D 1W 1M 3M 1Y 3Y 5Y Orchid Pharma Stock Performance 0.03 0.71 -2.02 36.39 155.45 237.87 0.00 Marksans Pharma Stock Performance -2.51 6.48 16.83 40.82 111.32 221.70 1583.74 FDC Ltd Stock Performance -0.77 0.82 5.27 13.54 38.96 56.08 228.70 Blue Jet Healthcare Stock Performance -0.49 1.34 8.77 30.30 0.00 0.00 0.00 Sun Pharma Adv Res. Stock Performance -1.53 5.51 -0.39 5.72 3.30 -21.50 59.55 All values in %
Insights
Stock Returns vs Nifty Midcap 100
Stock gave a 3 year return of 237.87% as compared to Nifty Midcap 100 which gave a return of 112.53%. (as of last trading session)Stock Returns vs Nifty Pharma
Stock generated 237.87% return as compared to Nifty Pharma which gave investors 64.02% return over 3 year time period. (as of last trading session)
Mutual Funds Ownership
MF Ownership as on 31 July 2024
484.83
Amount Invested (in Cr.)
1.98%
% of AUM
0.00
% Change (MoM basis)
187.31
Amount Invested (in Cr.)
1.08%
% of AUM
0.00
% Change (MoM basis)
87.15
Amount Invested (in Cr.)
1.07%
% of AUM
-13.83
% Change (MoM basis)
ADVERTISEMENT
Corporate Actions
Board Meeting
Quarterly Results
Aug 06, 2024
Board Meeting
Audited Results
May 16, 2024
Board Meeting
Quarterly Results
Feb 02, 2024
Announced on Ex-Date Dividend% May 15, 2012 Sep 13, 2012 30% May 18, 2011 Jul 19, 2011 30% May 28, 2010 Jul 12, 2010 100% Jun 30, 2009 Sep 17, 2009 10% May 29, 2008 Sep 18, 2008 30% Announced on Ex-Date Jul 18, 2005 Sep 15, 2005 Bonus Ratio: 1 share(s) for every 2 shares held No Data Available
Announced on Ex-Date Mar 15, 1995 Jan 09, 1995 Rights ratio: 1 share for every 1 held at a price of Rs 40.0 Announced on Meeting on Oct 23, 2023 Nov 29, 2023 - Jul 13, 2023 Aug 09, 2023 A.G.M. Jun 22, 2022 Jul 15, 2022 Book closure from Jul 8, 2022 to Jul 15, 2022 Jul 23, 2021 - Book closure from Aug 6, 2021 to Aug 13, 2021 Jul 23, 2021 - Book closure from Aug 6, 2021 to Aug 13, 2021
ADVERTISEMENT
About
Orchid Pharma Ltd., incorporated in the year 1992, is a Small Cap company (having a market cap of Rs 7,121.98 Crore) operating in Pharmaceuticals sector.
Orchid Pharma Ltd. key Products/Revenue Segments include Pharmaceutical Products, Other Materials, Sale of services and Other Operating Revenue for the year ending 31-Mar-2024.
For the quarter ended 30-06-2024, the company has reported a Consolidated Total Income of Rs 251.98 Crore, up 9.34 % from last quarter Total Income of Rs 230.46 Crore and up 36.35 % from last year same quarter Total Income of Rs 184.81 Crore. Company has reported net profit after tax of Rs 28.27 Crore in latest quarter.
The company’s top management includes Mr.Ram Gopal Agarwal, Mr.Ram Gopal Agarwal, Mr.Manish Dhanuka, Mr.Manish Dhanuka, Mr.Mridul Dhanuka, Mr.Mridul Dhanuka, Mr.Arjun Dhanuka, Mr.Arjun Dhanuka, Dr.Dharam Vir, Dr.Dharam Vir, Mr.Manoj Kumar Goyal, Mr.Manoj Kumar Goyal, Ms.Shubha Singh, Ms.Shubha Singh, Mrs.Tanu Singla, Mrs.Tanu Singla, Mr.Sunil Kumar Gupta, Mr.Sunil Kumar Gupta, Mr.Kapil Dayya, Mr.Kapil Dayya. Company has CNGSN & Associates LLP as its auditors. As on 30-06-2024, the company has a total of 5.07 Crore shares outstanding.
About Orchid Pharma
Orchid Pharma Ltd., incorporated in the year 1992, is a Small Cap company (having a market cap of Rs 7,121.98 Crore) operating in Pharmaceuticals sector. Orchid Pharma Ltd. key Products/Revenue Segments include Pharmaceutical Products, Other Materials, Sale of services and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-06-2024, the company has reported a Consolidated Total Income of Rs 251.98 Crore, up 9.34 % from last quarter Total Income of Rs 230.46 Crore and up 36.35 % from last year same quarter Total Income of Rs 184.81 Crore. Company has reported net profit after tax of Rs 28.27 Crore in latest quarter.The company’s top management includes Mr.Ram Gopal Agarwal, Mr.Ram Gopal Agarwal, Mr.Manish Dhanuka, Mr.Manish Dhanuka, Mr.Mridul Dhanuka, Mr.Mridul Dhanuka, Mr.Arjun Dhanuka, Mr.Arjun Dhanuka, Dr.Dharam Vir, Dr.Dharam Vir, Mr.Manoj Kumar Goyal, Mr.Manoj Kumar Goyal, Ms.Shubha Singh, Ms.Shubha Singh, Mrs.Tanu Singla, Mrs.Tanu Singla, Mr.Sunil Kumar Gupta, Mr.Sunil Kumar Gupta, Mr.Kapil Dayya, Mr.Kapil Dayya. Company has CNGSN & Associates LLP as its auditors. As on 30-06-2024, the company has a total of 5.07 Crore shares outstanding.
Industry
Key Indices Listed On
-
Address
Plot Nos. 121-128, 128A-133, 138-151, 159-164,SIDCO Industrial Estate, Alathur,Chengalpattu, Tamil Nadu - 600110
Executive Leadership
RG
Ram Gopal Agarwal
Chairman & Non-Exe.DirectorRG
Ram Gopal Agarwal
Chairman & Non-Exe.DirectorMD
Manish Dhanuka
Managing DirectorMD
Manish Dhanuka
Managing DirectorShow More
Auditors
Singhi & Co.
CNGSN & Associates LLP
Trending in Markets
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.